ArticleEuropean journal of pediatrics2025
Clinical and molecular characterization of 148 pediatric neurofibromatosis type 1 patients: a single-center study identifying 14 novel variants.
Article in European journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical and Molecular Portraits of Pediatric RASopathies: A Study of 118 Genotype-Confirmed Cases.Clinical genetics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurofibromatosis Type 1 (NF1) is a common genetic disorder of childhood, characterized by highly variable expressivity. In addition to café-au-lait spots, it shows multisystemic involvement and may cause skeletal abnormalities, tumor predisposition, and neurodevelopmental delay during childhood. This study aims to investigate the clinical and molecular characteristics of pediatric NF1 patients and to explore possible genotype-phenotype correlations. This study retrospectively evaluated the clinical and molecular findings of 148 pediatric NF1 patients, identifying genotype-phenotype correlations through Next-Generation Sequencing (NGS) and multiplex ligation-dependent probe amplification (MLPA) analysis. The mean age at diagnosis was 8.7 years (1 month to 17 years), with a male-to-female ratio of 0.8. Cafe-au-lait spots were the most common finding (99.3%), followed by freckling (46.6%) and Lisch nodules (28.4%). Additional findings included short stature (29.3%), scoliosis (11.4%), neurodevelopmental delay (14.9%), cutaneous neurofibromas (6.8%), plexiform neurofibromas (6.8%), and optic pathway gliomas (6.7%). Magnetic Resonance Imaging revealed T2 hyperintensities in 72.6% of cases. NGS identified NF1 variants in 94.5% of patients, and MLPA detected full-gene deletions in 2 additional cases. With a molecular diagnostic yield of 95.9%, this study identifies 14 novel variants.
conclusionThis study expands the NF1 variant spectrum in children and emphasizes the value of molecular testing for early diagnosis, especially in infants and those with atypical features. Age-stratified clinical data from a large pediatric cohort revealed a potential link between truncating variants and axillary/inguinal freckling. Beyond diagnosis, molecular testing also supports surveillance and genetic counseling, highlighting its clinical utility in managing pediatric NF1. WHAT IS KNOWN: • NF1 is a well-known genetic disorder with highly variable expressivity. It shows a wide range of clinical findings, even among patients with the same genetic variant. While some specific genotype-phenotype links have been reported, most NF1 variants do not show clear clinical patterns. Certain features, like café-au-lait macules, appear early in infancy, but others, such as freckling or neurofibromas, often appear later. WHAT IS NEW: • In our pediatric NF1 cohort, axillary/inguinal freckling was found to be significantly more common in patients with truncating variants. For Lisch nodules, cutaneous neurofibromas, tumor presence, and especially T2 hyperintensities, point estimates suggested a non-significant trend toward higher frequencies in the truncating group. This suggests that some features may differ depending on the type of mutation. A total of 14 novel variants in NF1 were identified through NGS.
Indexed as
Identifiers
41225058What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.